Newormics awarded SBIR Phase II grant from the NIMH

Newormics is excited to announce it has been awarded a $2.25M Phase II SBIR grant from the National Institutes of Health/National Institute of Mental Health (NIMH) for the continued development of the company’s in vivo imaging and screening technologies. Newormics core focus is to facilitate the use of C. elegans as a model organism for Read more about Newormics awarded SBIR Phase II grant from the NIMH[…]